WO2014017826A1 - Appareil pour inhalation de médicament - Google Patents

Appareil pour inhalation de médicament Download PDF

Info

Publication number
WO2014017826A1
WO2014017826A1 PCT/KR2013/006628 KR2013006628W WO2014017826A1 WO 2014017826 A1 WO2014017826 A1 WO 2014017826A1 KR 2013006628 W KR2013006628 W KR 2013006628W WO 2014017826 A1 WO2014017826 A1 WO 2014017826A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
evaporation
unit
aerosol
particles
Prior art date
Application number
PCT/KR2013/006628
Other languages
English (en)
Korean (ko)
Inventor
이규홍
허용주
Original Assignee
한국화학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국화학연구원 filed Critical 한국화학연구원
Publication of WO2014017826A1 publication Critical patent/WO2014017826A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/1075—Preparation of respiratory gases or vapours by influencing the temperature
    • A61M16/1085—Preparation of respiratory gases or vapours by influencing the temperature after being humidified or mixed with a beneficial agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/062—Desiccants

Definitions

  • the present invention relates to a drug inhalation device. More specifically, by removing water from the aqueous solution of the drug in the form of a liquid aerosol through the evaporation unit to convert the aqueous solution of the drug into a dry drug state to be inhaled through the inhalation device, the drug particles can penetrate deep into the lungs along the airways It can be applied to the treatment of lung disease or various treatments using the same, and the liquid aerosol state aqueous solution particles flowing from the aerosol unit can be converted into dry drug particles by removing moisture through the absorbent, thereby simplifying and miniaturizing the composition. It also relates to a convenient drug inhalation device that can be used continuously through simple hygroscopic change.
  • the drug inhalation device is a device that inhales the drug through the patient's airway, and is mainly used to treat diseases such as asthma and lung diseases, and recently, is used as a device for injecting various drugs through the nose or lungs. It is becoming.
  • the drug inhalation device is configured to aerosolize the aqueous solution of the drug in a state in which the drug is dissolved in water to fine particles to inhale the drug aerosol particles into the mouth or nose of the patient through a separate inhalation mechanism.
  • FIG. 1 is a conceptual diagram conceptually showing the configuration of a conventional drug inhalation device according to the prior art.
  • the conventional drug inhalation device is provided with a chemical solution storage unit 200 that can store the aqueous solution of the drug in the main body 100, as shown in Figure 1, the drug aqueous solution (W) stored in the chemical solution storage unit 200
  • An aerosol unit 300 for aerosolizing the () is provided inside the main body 100.
  • the aerosol unit 300 may aerosolize the aqueous drug solution W in a manner of supplying a separate compressed air, and may be configured in various ways such as an ultrasonic method or a jet injection method.
  • a separate intake tube (L) is connected to the aerosol unit 300, one end of the intake tube (L) is coupled to the suction device 400, such as a mask or mouthpiece to be mounted on the patient's respirator.
  • the aqueous drug solution particles W1 converted into the aerosol state by the aerosol unit 300 pass through the suction pipe L and are sucked into the respirator of the patient through the suction device 400 according to the patient's breathing.
  • the aqueous solution of drug solution W1 inhaled into the respirator of the patient is delivered to the bronchus or lung of the patient along the patient's airway.
  • the aqueous solution of the aqueous drug solution (W1) of the aerosol state generated by the aerosol unit 300 is a form in which the water particles (Q) wrap the outer space of the drug particles (P) present therein as shown in FIG. Since the size and weight is relatively large, in the process of being sucked into the patient's respiratory system through the inhalation mechanism 400, it is almost absorbed in the patient's mouth or throat, and does not penetrate deep into the lungs along the airways. .
  • the drug inhalation device does not penetrate the drug to the lung, it was used only for the purpose of treating the bronchial part, but there was a limit to the use of the drug for the treatment of pulmonary disease. In this case, the amount of penetration is relatively small, such that the amount of the drug used is also increased.
  • an object of the present invention is to remove the water from the aqueous solution of the drug solution in the liquid aerosol state through the evaporation unit to convert the aqueous drug solution particles into the dry drug particle state to provide a suction device
  • inhalation through the drug particles can penetrate deep into the lungs along the airways to provide a drug inhalation device that can be applied to the treatment of lung disease or various treatments using the same.
  • Another object of the present invention is to convert the liquid aerosol aqueous solution particles from the aerosol unit into the dry drug particles by removing the moisture through the moisture absorbent, so that the composition can be simplified and downsized, and can continue to be used through a simple absorbent exchange Maintenance is also to provide a convenient drug inhalation device.
  • Still another object of the present invention is to remove the water from the aqueous solution of the drug solution in the form of aerosol inlet from the aerosol unit by heating the heating module through the heating module to remove the water to dry drug particles, through the heating module with the absorbent from the drug solution particles
  • the present invention provides a drug inhalation device capable of removing moisture and converting it into dry drug particles having a higher degree of dryness.
  • the main body is formed with a chemical storage unit to store the drug solution therein, an aerosol unit for aerosolizing the drug solution stored in the drug storage unit, and the suction device connected to the aerosol unit mounted on the user's respirator
  • a drug inhalation device comprising: an evaporation unit for removing moisture from an aqueous solution of drug in an aerosol state produced by the aerosol unit to convert the drug solution particles into dry drug particles, wherein the evaporation unit includes the aerosol unit And a dry drug particle disposed between the suction device and the suction device is sucked into the respirator of the user through the suction device.
  • the evaporation unit an evaporation case in which an evaporation chamber is formed in the inner space;
  • a particle flow pipe passing through the evaporation case to pass through the evaporation chamber and having both ends connected to the aerosol unit and the suction device, respectively;
  • a moisture absorbent filled in the evaporation chamber wherein the particle flow pipe has a plurality of water flow holes formed to communicate with the evaporation chamber, and the aerosol drug aqueous solution particles introduced from the aerosol unit are the particle flow pipe.
  • the moisture absorbent may be configured to evaporate.
  • the particle flow pipe may be formed in the form of a metal mesh.
  • the particle flow pipe may be arranged in a zigzag form inside the evaporation chamber.
  • the particle flow pipe may be formed to branch into a plurality in the evaporation chamber.
  • the evaporation case may be an opening and closing door is formed on one side so that the moisture absorbent can be replaced.
  • the evaporation unit may further include an evaporation case in which an evaporation chamber is formed in an internal space; A particle flow pipe passing through the evaporation case to pass through the evaporation chamber and having both ends connected to the aerosol unit and the suction device, respectively; And it may be configured to include a heating module for heating the inner space of the particle flow pipe.
  • the heating module may be formed to surround the outer peripheral surface of the evaporation case.
  • the particle flow pipe is formed so as to pass through the evaporation case and to the outside, the heating module may be formed to surround the outer peripheral surface of the particle flow pipe in a section located outside the evaporation case.
  • the drug particles penetrate deeply into the lungs along the airways. It can be applied to the treatment of lung diseases or various treatments using the same can be used to extend the scope of the use, there is an effect that can reduce the amount of drugs do not cause the loss of drug particles.
  • liquid aerosol aqueous solution particles flowing from the aerosol unit are converted to dry drug particles by removing moisture through a moisture absorbent, so that the composition can be simplified and downsized, and it can be used continuously through a simple change of the absorbent so that maintenance is also convenient. There is an effect that can be done.
  • liquid aerosol aqueous solution particles flowing from the aerosol unit is removed by converting the water into dry drug particles by heating the heating module through the heating module, thereby removing the water from the aqueous drug particles through the heating module together with the hygroscopic agent. It can be converted into a dry drug particles of a higher degree of drying, so that the drug particles can penetrate deeper into the lungs.
  • FIG. 1 is a conceptual diagram conceptually showing the configuration of a conventional drug inhalation device according to the prior art
  • FIG. 2 is a conceptual diagram conceptually showing a configuration of a drug inhalation device according to an embodiment of the present invention
  • FIG. 3 is a view schematically showing a configuration of an evaporation unit of a drug inhalation device according to an embodiment of the present invention
  • FIG. 4 is a view schematically showing various forms of the particle flow pipe of the evaporation unit according to an embodiment of the present invention
  • FIG. 5 is a view schematically showing another form of the evaporation unit of the drug inhalation device according to an embodiment of the present invention.
  • FIG. 2 is a conceptual diagram conceptually showing a configuration of a drug inhalation device according to an embodiment of the present invention.
  • Drug inhalation device is a device for inhaling the drug through the respiratory system of the patient, the body 100 is formed in the receiving space therein, and provided inside the body 100 to store the aqueous solution of the drug
  • the main body 100 may be formed in a case shape in which an accommodation space is formed therein, and may be applied to both a fixed type or a portable type that can be held by a user at a hospital or home.
  • the chemical liquid storage unit 200 and the aerosol unit 300 are provided inside the main body 100, and the chemical liquid storage unit 200 and the aerosol unit 300 may be appropriate depending on whether the main body 100 is fixed or portable. It is mounted inside the main body 100 in size.
  • the drug solution storage unit 200 stores the drug solution W in a state in which the drug particles are dissolved in water, and the aerosol unit 300 is configured to aerosolize the drug solution solution W stored in the drug solution storage unit 200. do.
  • the aerosol unit 300 aerosolizes the aqueous drug solution (W) may be configured to supply compressed air through a separate air compressor, or may be configured by an ultrasonic method using an ultrasonic vibrator. Since the configuration of the aerosol unit 300 is widely used as a known technique, a detailed description thereof will be omitted.
  • the suction device 400 is connected to the aerosol unit 300 through the suction pipe L, and the suction device 400 such as a mask or a mouthpiece is coupled to one end of the suction pipe L so as to be mounted on the respirator of the user.
  • the evaporation unit 500 is disposed between the aerosol unit 300 and the suction mechanism 400, the evaporation unit 500 is connected to the aerosol unit 300 and the suction mechanism 400 through the suction pipe (L). .
  • the evaporation unit 500 receives the aerosol drug aqueous solution particles W1 generated by the aerosol unit 300 through the suction pipe L to remove water from the drug aqueous solution particles W1 to remove the water solution particles W1. Is converted to dry drug particles (P).
  • the evaporation unit 500 may be disposed inside the main body 100 as shown in FIG. 2, or may be separately disposed outside the main body 100.
  • the aqueous solution of drug solution W1 in the aerosol state generated by the aerosol unit 300 is converted into dry drug particles P from which moisture is removed via the evaporation unit 500 and then through the suction device 400. Inhaled by the user's respiratory system.
  • the aqueous solution of drug solution W1 in the aerosol state generated by the aerosol unit 300 may be filled with water particles Q in the outer space of the drug particles P present therein.
  • the evaporation unit 500 receives the aerosol drug aqueous solution particles W1 and functions to evaporate and remove moisture. That is, the evaporation unit 500 performs a function of converting the drug aqueous solution particles W1 that are liquid aerosol particles into dry drug particles P that are solid aerosol particles by evaporating moisture.
  • the aqueous aqueous solution particles W1 are continuously removed by evaporation of the external moisture particles W in the course of passing through the evaporation unit 500 as shown in FIG. 2, and finally, all of the moisture particles W are removed. Converted to removed dry drug particles (P).
  • the dry drug particles (P) is relatively small in size compared to the aqueous drug solution particles (W1), in general, the aqueous drug solution (W1) has a particle size of micro units, dry drug particles are nano- Has a particle size.
  • the dry drug particles P converted by the evaporation unit 500 are delivered to the suction device 400 through the suction pipe L, and thus, the dry drug particles P are sucked into the respirator of the user.
  • the drug aqueous solution particles W1 are converted into dry drug particles P through the evaporation unit 500, and thus, the dried drug particles P are converted. Since the suction through the inhalation mechanism 400 to the user's respiratory system, unlike the prior art drugs can penetrate deep into the lungs of the patient.
  • the liquid aerosol drug aqueous solution particles (W1) is relatively large in size and weight, as described in the prior art, and thus, in the process of being sucked into the respiratory system of the patient through the inhalation mechanism 400, in the mouth, throat, etc. of the patient. While almost absorbed and unable to penetrate deep into the lungs along the airways, the dry drug particles (P) in the aerosol-free solid aerosol state have a particle size in nano units in the solid aerosol state and are light in weight. Breathing may penetrate deep into the lungs.
  • the drug inhalation device can be used for the treatment of pulmonary diseases as well as for the treatment of bronchus, etc., and can be used for various methods of treatment such as deeply penetrating drug particles into the lungs and circulating blood. .
  • FIG 3 is a view schematically showing a configuration of an evaporation unit of a drug inhalation device according to an embodiment of the present invention
  • Figure 4 is a various forms for the particle flow pipe of the evaporation unit according to an embodiment of the present invention It is a schematic drawing.
  • the evaporation unit 500 of the drug inhalation device passes through an evaporation case 510 and an evaporation chamber 513 in which an evaporation chamber 513 is formed in an internal space. And a particle flow pipe 520 passing through the evaporation case 510, and a moisture absorbent 530 filled in the evaporation chamber 513.
  • connection port 511 into which the suction pipe L is inserted to be connected to the aerosol unit 300 and the suction mechanism 400, respectively, and on one side of the evaporation case 510 an evaporation chamber ( 513, the opening and closing door 512 that can open and close the interior is formed to replace the absorbent 530 filled in the interior space.
  • the particle flow pipe 520 is disposed inside the evaporation case 510 so as to communicate with the connection port 511, and both ends thereof are connected to the aerosol unit 300 and the suction device 400 through the suction pipe L, respectively. Accordingly, the aerosol drug aqueous solution particles W1 generated by the aerosol unit 300 flow into the particle flow pipe 520 through the suction pipe L, and then again through the suction pipe L, the suction device 400. Flow to.
  • a plurality of moisture flow holes 521 are formed in a uniform distribution so as to communicate with the evaporation chamber 513. For example, as shown in FIG.
  • the particle flow pipe 520 may be formed in the form of a metal mesh of a metal material, and in this case, the mesh gap may function as the water flow hole 521.
  • the mesh gap may function as the water flow hole 521.
  • the particle flow pipe 520 may be formed in a simple hollow pipe form in a manner that a plurality of water flow holes 521 is formed in a uniform distribution in all sections.
  • the moisture absorbent 530 may be a material that absorbs moisture.
  • a silica gel may be used, and other materials may be used.
  • the moisture absorbent 530 is filled in the evaporation chamber 513 in the form of granules, and the water from the drug aqueous solution particles W1 passing through the particle flow pipe 520 through the water flow hole 521 of the particle flow pipe 520. Absorb it.
  • the water flow hole 521 of the particle flow pipe 520 is preferably formed of a smaller diameter than the moisture absorbent 530 so that the moisture absorbent 530 does not pass.
  • the aqueous solution of drug solution W1 in the aerosol state generated by the aerosol unit 300 is introduced into the particle flow pipe 520 through the suction pipe L, and then passes through the particle flow pipe 520.
  • moisture is absorbed by the absorbent 530 and is converted into a dry drug particle (P) state.
  • the dry drug particles P converted as described above are supplied to the suction device 400 through the suction pipe L, and are sucked into the respirator of the user through the suction device 400.
  • the aqueous solution particle W1 is absorbed into the absorbent 530 through the plurality of water flow holes 521 in the course of passing through the particle flow pipe 520, the amount of water absorbed into the aqueous solution particle W1 is increased. In order to increase, it is preferable to lengthen the flow path of the particle flow pipe 520 so that moisture is absorbed for a sufficient time.
  • the particle flow pipe 520 is disposed in a zigzag form in the evaporation chamber 513, whereby the drug aqueous solution particles W1 pass through the particle flow pipe 520. Moisture absorption time can be increased for more highly dried dry drug particles (P) states.
  • the particle flow pipe 520 is formed to branch into two inside the evaporation chamber 513, whereby each particle flow pipe 520 in which the drug aqueous solution particles W 1 are branched. Water may be absorbed by the moisture absorbent 530 and may be converted into a more highly dried dry drug particle (P) state.
  • the particle flow pipe 520 may be branched into two but may be branched into two or more.
  • FIG. 5 is a view schematically showing another form of the evaporation unit of the drug inhalation device according to an embodiment of the present invention.
  • the heating module 540 may be additionally mounted.
  • the evaporation unit 500 penetrates the evaporation case 510 through which the evaporation chamber 513 is formed in the internal space, and passes through the evaporation case 510 so as to pass through the evaporation chamber 513.
  • Particle flow pipe 520 connected to the aerosol unit 300 and the suction mechanism 400, respectively, and a heating module 540 for heating the inner space of the particle flow pipe 520 may be configured.
  • the evaporation case 510 and the particle flow pipe 520 may be applied in the same manner as described above, so a detailed description thereof will be omitted.
  • the particle flow pipe 520 since the inner space of the particle flow pipe 520 is heated through the heating module 540 to accelerate moisture evaporation, the particle flow pipe 520 does not have to be provided with a plurality of water flow holes 521.
  • the moisture absorption method by the moisture absorbent 530 and the heating evaporation method by the heating module 540 as shown in Figure 5, the water flow hole 521 in the particle flow pipe 520 It must be formed.
  • the heating module 540 is formed to surround the outer circumferential surface of the evaporation case 510 as shown in (a) of FIG. 5 to heat the evaporation chamber 513, and then, particles are heated by the evaporation chamber 513.
  • the internal space of the flow pipe 520 may be configured by indirect heating.
  • the heating module 540 may be configured to surround the outer circumferential surface of the particle flow pipe 520 and directly heat the space inside the particle flow pipe 520.
  • the heating module 540 may be disposed inside the evaporation chamber 513, but as shown in FIG. 5B, the particle flow pipe 520 passes through the evaporation case 510 and extends to the outside.
  • the heating module 540 may be formed to surround the outer circumferential surface of the particle flow pipe 520 in a section located outside the evaporation case 510.
  • the aqueous solution of the drug solution W1 in the aerosol state passing through the particle flow pipe 520 is absorbed by the moisture absorbent 530 and at the same time accelerated evaporation by the heating module 540, further drying Water is removed in the state and converted into dry drug particles (P).
  • the heating module 540 may be configured in various forms, but as shown in FIG. 5, a heating cover 541 having a ductility of a fiber material, and a heating coil disposed in an inner space of the heating cover 541. 542 and a filling material 542 filling the inner space of the heating cover 541 to transfer heat of the heating coil 542.
  • the heating coil 542 may be configured to generate heat by receiving power.
  • the heating module 540 may be flexible and may wrap the evaporation case 510 or the particle flow pipe 520, thereby minimizing heat loss.
  • the heating module 540 may be configured in various forms to exhibit a heat generating function such as chemical pyrolysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un appareil pour inhalation de médicament, dans lequel des particules d'une solution aqueuse médicamenteuse sous forme d'aérosol liquide sont converties en particules médicamenteuses sèches par élimination de l'humidité de celles-ci au moyen d'une unité d'évaporation de façon à être inhalées à l'aide d'un dispositif d'inhalation, de sorte que les particules médicamenteuses pénètrent profondément le long de l'arbre respiratoire jusqu'aux poumons, cet appareil pouvant ainsi être utilisé dans le traitement de maladies pulmonaires ou dans divers autres traitements au moyen dudit appareil. Dans ledit appareil, des particules d'une solution aqueuse médicamenteuse sous forme d'aérosol liquide, s'écoulant à partir d'une unité aérosol, sont converties en particules médicamenteuses sèches au moyen d'un absorbant d'humidité, ce qui permet d'obtenir un appareil pour inhalation simplifié et de taille réduite, pouvant être utilisé de manière continue par simple échange de l'absorbant d'humidité, l'entretien étant ainsi facilité.
PCT/KR2013/006628 2012-07-24 2013-07-24 Appareil pour inhalation de médicament WO2014017826A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0080790 2012-07-24
KR1020120080790A KR101373981B1 (ko) 2012-07-24 2012-07-24 약물 흡입 장치

Publications (1)

Publication Number Publication Date
WO2014017826A1 true WO2014017826A1 (fr) 2014-01-30

Family

ID=49997570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/006628 WO2014017826A1 (fr) 2012-07-24 2013-07-24 Appareil pour inhalation de médicament

Country Status (2)

Country Link
KR (1) KR101373981B1 (fr)
WO (1) WO2014017826A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108392844A (zh) * 2018-04-19 2018-08-14 苏州阿洛斯环境发生器有限公司 一种固体颗粒物发生方法以及发生器

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010101991A (ko) * 1999-02-03 2001-11-15 간덴 데, 죠스트 에. 리포좀 분말 에어로졸의 폐적용을 위한 압축 공기 흡입기및 그에 적합한 분말 에어로졸
JP2007097830A (ja) * 2005-10-04 2007-04-19 Omron Healthcare Co Ltd 吸入器および吸入器用マウスピース
KR20070073865A (ko) * 2004-10-06 2007-07-10 베링거 인겔하임 인터내셔날 게엠베하 분배장치, 저장장치 및 분말 분배 방법
KR20090114436A (ko) * 2007-02-28 2009-11-03 마이크로도스 테라퍼스, 인코포레이티드 흡입기

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010101991A (ko) * 1999-02-03 2001-11-15 간덴 데, 죠스트 에. 리포좀 분말 에어로졸의 폐적용을 위한 압축 공기 흡입기및 그에 적합한 분말 에어로졸
KR20070073865A (ko) * 2004-10-06 2007-07-10 베링거 인겔하임 인터내셔날 게엠베하 분배장치, 저장장치 및 분말 분배 방법
JP2007097830A (ja) * 2005-10-04 2007-04-19 Omron Healthcare Co Ltd 吸入器および吸入器用マウスピース
KR20090114436A (ko) * 2007-02-28 2009-11-03 마이크로도스 테라퍼스, 인코포레이티드 흡입기

Also Published As

Publication number Publication date
KR101373981B1 (ko) 2014-03-12
KR20140014545A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
WO2014017827A1 (fr) Appareil pour inhalation de médicament
CN100464797C (zh) 灭毒型呼吸辅助治疗机
CN104208791B (zh) 一种呼吸插管用人工鼻
CN206745708U (zh) 一种儿科呼吸治疗用雾化器
WO2014017826A1 (fr) Appareil pour inhalation de médicament
CN208710713U (zh) 一种急诊内科专用应急呼吸装置
CN206081256U (zh) 一种用于气管插管的多功能插接装置
CN211096792U (zh) 一种重症医学患者呼吸恢复辅助装置
CN106163600B (zh) 用于对气溶胶进行加湿的加湿器
JP3230416U (ja) 医療及び保健用のアイマスク
CN212439624U (zh) 一种呼吸内科用雾化器
CN211272971U (zh) 一种果味麻醉加湿过滤呼吸废气装置
CN114306837A (zh) 一种儿科呼吸内科用雾化器
CN204106767U (zh) 用于呼吸回路的雾化给药系统
KR20100090473A (ko) 긴급 피난용 마스크의 산소발생장치
WO2020029469A1 (fr) Dispositif d'atomisation portable spécial unité de soins intensifs permettant une respiration autonome en fonction de l'écoulement d'air
CN204864462U (zh) 一种气切型热湿交换器
CN219764222U (zh) 一种滤芯利用率高的人工鼻
CN213220145U (zh) 一种雾化气的加热装置
CN214912010U (zh) 呼吸内科哮喘治疗器
CN109363683A (zh) 一种呼吸停止报警装置
CN211513010U (zh) 一种小儿呼吸道保护护理装置
CN212756773U (zh) 多功能气管导管套舱
CN219983627U (zh) 用于防治喉部水肿的咽喉部雾气器
KR102517592B1 (ko) 멤브레인 구조를 갖는 호흡순환튜브

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13823143

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13823143

Country of ref document: EP

Kind code of ref document: A1